FH

Fatema Hussain Karimi

Active Director Director DIN 10389238
DIN 10389238 First appointment Nov 2023
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Nov 2023
Shareholding value •••• Premium profile

About Fatema Hussain Karimi

Data last updated:

Fatema Hussain Karimi is a Director at Homoeopathic Journal India Foundation (since 2023). Homoeopathic Journal India Foundation reported revenue of ₹9.6 Lakh (FY 2025).

DIN 10389238
Primary Designation Director
First Appointment 10 Nov 2023
Oldest Company Age 2 yrs
Largest company Homoeopathic Journal India Foundation · ₹9.6 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director10 Nov 20232023₹9.6 Lakh (FY 2025)Active

Board colleagues of Fatema Hussain Karimi

Directorship timeline

Open interactive timeline →
Homoeopathic Journal India Foundation
Premium access

Shareholding and investment profile for Fatema Hussain Karimi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Fatema Hussain Karimi

Fatema Hussain Karimi currently holds 1 directorship: Homoeopathic Journal India Foundation (Director, since 10 Nov 2023, revenue ₹9.6 Lakh (FY 2025)).

Fatema Hussain Karimi was first appointed on 10 Nov 2023 as Director at Homoeopathic Journal India Foundation.

The current boards of Fatema Hussain Karimi's companies include Chandra Mohan Asrani (Homoeopathic Journal India Foundation), Sushma Harishyam Jaiswal (Homoeopathic Journal India Foundation).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available